Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 2/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | PLAU | P00749 | 2/20 | 0.45 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8890461 | 0.93 | LCK (0.50) | PTPN11LCKCA1CA2CA12 | |
| SCHEMBL29365729 | 0.84 | PTPN11 (0.68) | PTPN11LCKCA1CA2CA12 | |
| SCHEMBL69025 | 0.84 | PTPN11 (0.68) | PTPN11LCKCA1CA2CA12 | |
| SCHEMBL8732524 | 0.82 | PTPN11 (0.66) | PTPN11LCKCA1CA2CA12 | |
| SCHEMBL15711096 | 0.81 | CYP2A6 (0.50) | CA2MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL6606896 | 0.80 | PLAU (0.57) | HTTPLAUHPGDHDAC1SMN1; SMN2 | |
| SCHEMBL9979782 | 0.80 | PTPN11 (0.64) | PTPN11LCKCA1CA2CA12 | |
| SCHEMBL8748193 | 0.80 | MAPT (0.49) | CA12CA9ALOX15MAPTKDM4E | |
| SCHEMBL294464 | 0.80 | CA12 (0.51) | PTPN11CA1CA2CA12CA7 | |
| SCHEMBL8748414 | 0.79 | ESR1 (0.54) | HPGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160187-B1 | SPIROINDALONES | MERCK SHARP & DOHME (US) | 2013-05-22 | — | — | EP | claimed |
| US-8309544-B2 | Spiroindalones | MERCK SHARP & DOHME CORP. (US) | 2012-11-13 | — | — | US | claimed |
| US-20100137297-A1 | SPIROINDALONES | MERCK SHARP & DOHME LLC | 2010-06-03 | — | — | US | claimed |
| CN-101678011-A | Spiro-indolinone compounds | MERCK & CO INC | 2010-03-24 | — | — | CN | claimed |
| EP-2160187-A1 | SPIROINDALONES | Merck Sharp & Dohme Corp. (US) | 2010-03-10 | — | — | EP | claimed |
| WO-2008144266-A1 | SPIROINDALONES | MERCK & CO., INC. (US) | 2008-11-27 | — | — | WO | claimed |
| CN-1582287-A | Thiophenylthiopyrane dioxides as MMP or TNF-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-02-16 | — | — | CN | claimed |
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | claimed |
| EP-1423386-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | claimed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | claimed |
| CN-117651552-A | Therapeutic or prophylactic agent for covd-19 | 国立大学法人广岛大学 | 2024-03-05 | — | — | CN | disclosed |
| CN-111201215-B | Novel amide compound, pin1 inhibitor using same, therapeutic agent for inflammatory disease, and therapeutic agent for cancer | 国立大学法人广岛大学 | 2024-01-26 | — | — | CN | disclosed |
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | HIROSHIMA UNIVERSITY (JP) | 2024-01-25 | — | — | US | disclosed |
| EP-4248997-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR COVID-19 | Hiroshima University (JP) | 2023-09-27 | — | — | EP | disclosed |
| EP-3178323-B1 | NOXIOUS ARTHROPOD CONTROL AGENT CONTAINING AMIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2021-06-23 | — | — | EP | disclosed |
| US-5391806-A | A storage stable chromogens as color-developing agent or stabilizers | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-02-21 | — | — | US | disclosed |
| US-5306688-A | Color-forming, electron donating compound and electron accepting compound; storage stability of uncolored portion | MITSUI TOATSU CHEMICALS, INC. (JP) | 1994-04-26 | — | — | US | disclosed |
| US-5270281-A | Chromogenic compound | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1993-12-14 | — | — | US | disclosed |
| EP-0534257-A1 | Salicylic acid derivatives, the process for preparing the same and the heat-sensitive recording materials comprising thereof | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-03-31 | — | — | EP | disclosed |
| EP-0524419-A1 | Heat-sensitive recording materials and phenol compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | TNF, MMP9, MMP1 | PTPN11 734/4885LCK 2738/4885CA1 612/4885 |
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | PIN1, ACE2, ACE | PTPN11 515/4885LCK 192/4885CA1 1563/4885 |
| US-20100137297-A1 | SPIROINDALONES | HIF1AN, HIF1A, EGLN2 | PTPN11 3495/4885LCK 4802/4885CA1 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.